Acute Kidney Injury Market Size in the 7MM is Estimated to Exceed USD 9,904.0 Million by 2035

The 7 major acute kidney injury markets reached a value of US$ 5,766.5 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 9,904.0 Million by 2035, exhibiting a growth rate (CAGR) of 5.04% during 2025-2035.

The acute kidney injury market is registering strong interest in the healthcare sector driven by the increased global burden of kidney disorders. Acute kidney injury refers to an abrupt loss of kidney function, usually over hours or days, resulting in the buildup of waste products and fluid within the body. It usually arises as a complication of another serious illness or due to conditions like sepsis, trauma, dehydration, or certain drugs. The condition can be reversed if diagnosed and managed early, but in the absence of early intervention, it can progress to chronic kidney disease or even result in death. As of 2025, the AKI market is experiencing robust growth due to heightened awareness, hospital admission rate increases, and the emergence of novel therapies and diagnostic technologies.

A key driver in the market is the growing incidence of risk factors such as diabetes, hypertension, and cardiovascular disease. These ailments drastically increase the risk of acute kidney injury, particularly among the elderly. As the world population rapidly ages, particularly in the developed world, the prevalence of AKI is bound to increase, necessitating a greater need for effective diagnostics, therapeutics, and hospital care. Moreover, the number of surgeries, particularly cardiac and orthopedic surgeries, has increased, which enhances the risk of AKI in patients undergoing critical care.

Request for a sample of this report: https://www.imarcgroup.com/acute-kidney-injury-market/requestsample

Another key driver of the acute kidney injury market in 2025 is the evolution in diagnostic technology. Point-of-care tests that identify early signs of kidney injury, including neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C, are being adopted in practice. These devices assist in the early identification of kidney injury before conventional symptoms such as decreased urine output or elevated creatinine are evident. The sooner AKI is detected, the greater the potential to forestall its advancement, decreasing healthcare expenditures while enhancing the outcomes of patients.

Pharmaceutical and biotech firms are investing heavily in the creation of targeted therapies for AKI. Before, the treatment strategy involved predominantly supportive care, like fluid resuscitation, dialysis, and treating the underlying cause. Current research, however, is geared towards the identification of drugs that are capable of preventing or repairing kidney injury at the cellular level. A number of clinical trials are being conducted to assess new therapeutic agents directed against inflammation, oxidative stress, and renal ischemia, which are key pathways implicated in the development of AKI.

Ask the Analyst for Customization and Get Full Insights with TOC: https://www.imarcgroup.com/request?type=report&id=6882&flag=E

This report also provides a detailed analysis of the current acute kidney injury marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Competitive Landscape With Key Players:

The competitive landscape of the acute kidney injury market has been studied in the report with the detailed profiles of the key players operating in the market.

Sentien Biotechnologies
Novartis
Guard Therapeutics
Renibus Therapeutics
Ocelot Bio

IMARC Group Offers Other Reports:

Vertigo market https://www.imarcgroup.com/vertigo-market

Polycythemia Vera Market https://www.imarcgroup.com/polycythemia-vera-market

Eosinophilic Esophagitis Market https://www.imarcgroup.com/eosinophilic-esophagitis-market

Chimeric Antigen Receptor (CAR) T-Cell Therapy market https://www.imarcgroup.com/chimeric-antigen-receptor-t-
cell-therapy-market

Mesothelioma Market https://www.imarcgroup.com/mesothelioma-market

Lymphedema Market https://www.imarcgroup.com/lymphedema-market

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.